Controlled release formulation of ranitidine-containing montmorillonite and Eudragit E-100.
OBJECTIVE
The objective of this work was to illustrate the suitability of montmorillonite (MMT) as a drug delivery carrier, by developing a new clay-drug composite of ranitidine hydrochloride (RT) intercalated in MMT.


METHODS
The MMT-RT composite was prepared by ion-exchange process. X-ray diffraction and Fourier transform infrared spectra were employed to confirm the intercalation of RT in the MMT interlayers. The prepared MMT-RT hybrid was coated with cationic polymer Eudragit E-100 by oil-in-water solvent evaporation method. The release processes of RT from MMT-RT and MMT-RT/Eudragit E-100 were monitored under in vitro condition in the gastric fluid.


RESULTS
X-ray diffraction and Fourier transform infrared spectra analysis indicated the intercalation of RT molecules within the clay lattice. The in vitro release studies showed that MMT-RT released RT in a controlled manner. In the case of MMT-RT/Eudragit E-100, both the release rate and the release percentages noticeably increased in the presence of Eudragit E-100, because of its effective exchange with intercalated RT molecules. The release kinetics followed parabolic diffusion mechanism.


CONCLUSIONS
MMT has great potential as a drug delivery carrier with various scenarios. The dosage of the MMT-RT/Eudragit E-100 can be in the tablet form. The hybrid material and polymer-coated hybrids are microparticles.
Joshi
Ghanshyam V
GV
Discipline of Inorganic Materials and Catalysis, Central Salt and Marine Chemicals Research Institute, Council of Scientific and Industrial Research (CSIR), Bhavnagar, Gujarat, India.
Kevadiya
Bhavesh D
BD
Bajaj
Hari C
HC
D000179:Acrylates / Q000737:chemistry*; D000897:Anti-Ulcer Agents / Q000737:chemistry*; D001546:Bentonite / Q000737:chemistry*; D003198:Computer Simulation; D003692:Delayed-Action Preparations / Q000737:chemistry*; D004058:Diffusion; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005079:Excipients; D006863:Hydrogen-Ion Concentration; D011108:Polymers / Q000737:chemistry*; D011899:Ranitidine / Q000737:chemistry*; D012995:Solubility
D000179:Acrylates; D000897:Anti-Ulcer Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; C477020:Eudragit E100; D005079:Excipients; D011108:Polymers; D001546:Bentonite; D011899:Ranitidine